MedTrace Logo

Bevacizumab Therapy for Brain Arteriovenous Malformation

NCT02314377 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2020-03-03

No results posted yet for this study

Summary

Bevacizumab Therapy for brain arteriovenous malformation that is not amenable to surgical intervention.

Conditions

  • Brain Arteriovenous Malformation

Interventions

DRUG

Bevacizumab

Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).

Sponsors & Collaborators

Principal Investigators

  • Daniel Cooke, MD · UCSF Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-12-01
Completion
2019-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02314377 on ClinicalTrials.gov